Evidence map›Paper›PMID 37078275›Full record

ArticleBioconjugate chemistry2023

Image-Guided Enhanced PDT/PTT Combination Therapy Using Brominated Hemicyanine-Loaded Folate Receptor-Targeting Ag

Eda Celikbas, Ayca Saymaz, Hande Gunduz, Irem Koc, Ece Cakir, Alphan Sennaroglu, Safacan Kolemen, Havva Yagci Acar, Kubra Onbasli

Open access · hybridAbstract read
In one paragraph

Article in Bioconjugate chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Eda CelikbasDepartment of Chemistry, Koç University, Rumelifeneri Yolu, Sariyer, Istanbul 34450, Turkey.ORCID 0000-0003-4882-6445
Ayca SaymazDepartment of Chemistry, Koç University, Rumelifeneri Yolu, Sariyer, Istanbul 34450, Turkey.
Hande GunduzDepartment of Chemistry, Koç University, Rumelifeneri Yolu, Sariyer, Istanbul 34450, Turkey.
Irem KocGraduate School of Materials Science and Engineering, Koç University, Rumelifeneri Yolu, Istanbul 34450, Turkey.ORCID 0000-0003-2253-599X
Ece CakirGraduate School of Materials Science and Engineering, Koç University, Rumelifeneri Yolu, Istanbul 34450, Turkey.
Alphan SennarogluKUYTAM, Koç University Surface Science and Technology Center, Koc University, Rumelifeneri Yolu, Istanbul 34450, Turkey.ORCID 0000-0003-4391-0189
Safacan KolemenDepartment of Chemistry, Koç University, Rumelifeneri Yolu, Sariyer, Istanbul 34450, Turkey.ORCID 0000-0003-4162-5587
Havva Yagci AcarDepartment of Chemistry, Koç University, Rumelifeneri Yolu, Sariyer, Istanbul 34450, Turkey.ORCID 0000-0001-5601-8814
Kubra OnbasliDepartment of Metallurgical and Materials Engineering, Istanbul Technical University, Istanbul 34469, Turkey.ORCID 0000-0001-6573-8565
Koç University · TRIstanbul Technical University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-targeting nanoparticles and phototherapies are the two major trends in tumor-specific, local cancer therapy with minimal side effects. Organic photosensitizers (PSs) usually offer effective photodynamic therapy (PDT) but require enhanced solubility and tumor-targeting, which may be provided by a nanoparticle. Near-infrared (NIR)-emitting Ag

Indexed as

NanoparticlesPhotochemotherapyQuantum DotsCarbocyaninesFolic AcidHeLa CellsHumansPhotosensitizing AgentsPhototherapyCarbocyaninesFolic AcidPhotosensitizing Agentstetramethylene hemicyanine

Identifiers

PMID37078275
PMCPMC10197082
OpenAlexW4366463066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.